



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

**P&T Date: 04/10/2025**

**Evenity® (romosozumab-aqqg)**

**HCPCS: J3111**

**Policy:**

*Requests must be supported by submission of chart notes and patient specific documentation.*

- A. Coverage of the requested drug is provided when all the following are met:
  - a. Diagnosis of osteoporosis with a T-score of less than or equal to -2.5, history of a fragility fracture, or high FRAX fracture probability (defined as a 10-year major osteoporotic fracture risk greater than or equal to 20% or hip fracture risk greater than or equal to 3%)
  - b. If member has very high risk osteoporosis: Trial and failure (such as reduction of T-score or fracture) of zoledronate OR if zoledronate is contraindicated a preferred denosumab product
    - i. Very high risk meets ONE of the following criteria:
      - a) Recent fracture (e.g., within the past 12 months)
      - b) Fractures while on approved osteoporosis therapy
      - c) Multiple fractures
      - d) Fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids)
      - e) Very low T-score (e.g., less than - 3.0)
      - f) High risk for falls or history of injurious falls
      - g) Very high fracture probability by FRAX® (fracture risk assessment tool) (e.g., major osteoporosis fracture > 30%, hip fracture > 4.5%) or other validated fracture risk algorithm
  - c. If member is high risk: Trial and failure (such as reduction of T-score or fracture) of oral or IV bisphosphonates AND preferred denosumab product unless contraindicated
  - d. Will not be used in combination with bisphosphonates, another anabolic bone-modifying agent or denosumab
  - e. Trial and failure, contraindication, or intolerance to the preferred drugs as listed in BCBSM/BCN's prior authorization and step therapy documents
- B. Quantity Limitations, Authorization Period and Renewal Criteria
  - a. Quantity Limits: Align with FDA recommended dosing
  - b. Authorization Period: 12 months
  - c. Renewal Criteria: Not applicable as no further authorization will be provided

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

\*\*\*Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

### Background Information:

- Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
- Approximately 54 million people in the United States have osteoporosis or another form of low bone mass. Breakdown of bone structure may be the result of natural aging and calcium deficiency (e.g., senile osteoporosis) or due to hormonal changes as in post-menopause. The decrease in bone mass and deterioration of bone tissue in osteoporosis can result in bone fragility and potential for fractures. Fractures related to osteoporosis and bone loss are a concern because of the high morbidity and mortality rate and economic burden. The National Osteoporosis Foundation estimates that 1 in 2 women and 1 in 4 men over 50 years of age will break a bone as a result of osteoporosis, resulting in \$19 billion in related costs every 2 years and 2 million broken bones.
- The American Association for Clinical Endocrinology (AACE)/American College of Endocrinology (ACE) Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis (2020) consider a diagnosis of osteoporosis and recommend pharmacologic therapy for the following clinical scenarios:
  - Presence or history of fragility fractures in the absence of other metabolic bone disorders, even in those with normal bone mineral density (BMD) as measured by axial dual-energy X-ray absorptiometry (DXA) scan
  - T-score of -2.5 or lower in the lumbar spine, femoral neck, total hip, or 1/3 radius; measured by DXA scan
  - T-score between -1.0 and -2.5 and if the FRAX<sup>®</sup> (fracture risk assessment tool) 10-year probability for major osteoporotic fracture is  $\geq 20\%$  or the 10-year probability of hip fracture is  $\geq 3\%$  in the United States or above the country-specific threshold in other countries or regions
    - The FRAX<sup>®</sup> tool ([www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)) was developed by the World Health Organization (WHO) to evaluate fracture risk of patients. It integrates clinical risk factors with BMD at the femoral neck. The FRAX<sup>®</sup> tool provides the 10-year probability of fracture. The output is a 10-year probability of hip fracture and a 10-year probability of major osteoporotic fracture (forearm, shoulder, or clinical vertebral fracture).
- AACE/ACE guidelines separate patients with osteoporosis into two categories – high risk or very high risk. Patients who have had a recent fracture (e.g., within the past 12 months), fractures while on approved osteoporosis therapy, multiple fractures, fractures while on drugs causing skeletal harm (e.g., long-term glucocorticoids), very low T-score (e.g., less than -3.0), high risk for falls or history of injurious falls, and very high fracture probability by FRAX<sup>®</sup> (e.g., major osteoporosis fracture > 30%, hip fracture > 4.5%) or other validated fracture risk algorithm should be considered to be at very high fracture risk. All other patients who have been diagnosed with osteoporosis but are not at very high fracture risk, as defined above, are considered to be high risk.

- The Endocrine Society 2020 Guidelines for the Pharmacological Management of Osteoporosis in Postmenopausal Women separate patients into 4 categories. Their high risk and very high risk categories align with those defined by the AACE/ACE guidelines. However, they also identify patients as low risk if they have no prior hip or spine fractures, a BMD T-score at the hip and spine both above -1.0, a 10-year hip fracture risk < 3%, and 10-year risk of major osteoporotic fractures < 20% or moderate risk when they have no prior hip or spine fractures, a BMD T-score at the hip and spine both above -2.5, and 10-year hip fracture risk < 3% or risk of major osteoporotic fractures < 20%.
- AACE/ACE guidelines recommend bisphosphonates (alendronate, risedronate, IV zoledronate) and Prolia (denosumab) the initial treatment option for patients with high-risk osteoporosis without prior fracture. Bisphosphonates decrease the breakdown of the bone (antiresorptive) and have been shown to increase BMD and reduce the incidence of fractures in patients with osteoporosis. Contraindications to bisphosphonates include hypocalcemia and severe renal impairment. In addition, oral bisphosphonates are contraindicated in patients with the inability to stand or sit upright for at least 30 minutes and may not be an appropriate option in patients with underlying gastrointestinal issues. However, use of an IV bisphosphonate is still appropriate in these situations. Prolia (denosumab) is another antiresorptive therapy that prevents the interaction of receptor activator of nuclear factor- $\kappa$ B ligand (RANKL) with its receptor on osteoclasts and osteoclast precursors and reversibly inhibits osteoclast-mediated bone resorption.
- AACE/ACE guidelines include evidence supporting superiority of certain antiresorptive agents (Prolia and IV zoledronate) and anabolic agents (Evenity, Tymlos<sup>®</sup>, and Forteo<sup>®</sup>) over oral bisphosphonates for individuals who are unable to use oral bisphosphonates and as initial therapy or for individuals with osteoporosis who are at very high risk for fracture. These guidelines do not give preference to one therapy over another.
- The Endocrine Society guidelines recommend initial treatment of patients at moderate risk with bisphosphonates (oral or IV) as initial therapy. For patients in the high to very high risk categories, the treatment algorithm recommends bisphosphonates, denosumab, teriparatide, abaloparatide, or romosuzumab all with adjunct calcium and vitamin D therapy as their treatment options.
- Guidelines recommend sequential treatment with antiresorptive osteoporosis therapies to maintain BMD gains and reduce fracture risk after completing a course of treatment with anabolic drugs.
- Until the effect of combination therapy on fracture risk is better understood, the AACE does not recommend concomitant use of FDA approved osteoporosis agents for the prevention or treatment of postmenopausal osteoporosis.
- Guidelines also do not recommend use of one anabolic agent over another as there is insufficient evidence to establish one as safer or more effective than another.
- The goal of monitoring osteoporosis is to identify those who have significant bone loss. AACE recommends repeat DXA scan every 1 to 2 years after initiation of therapy until BMD is stable. Bone turnover markers (BTMs) are also useful for assessing patient compliance and efficacy of therapy. Reductions in BTMs are conferred by antiresorptive therapy and are associated with fracture reduction. Significant increases in BTMs indicate good response to anabolic therapy.
- Evenity is limited to a 12 month duration of treatment. After 12 monthly doses, the anabolic effect of Evenity wanes, which is the reason for the duration limit. If osteoporosis therapy is still necessary, continued treatment with an antiresorptive agent should be considered (e.g., a bisphosphonate).

**References:**

1. Forteo [prescribing information]. Indianapolis, IN: Eli Lilly; July 2024.
2. Teriparatide [prescribing information]. Morristown, NJ: Alvogon; November 2023.
3. Tymlos [prescribing information]. Waltham, MA: Radius Health; December 2023.
4. Evenity [package insert]. Thousand Oaks, CA: Amgen; April 2020.
5. Bisphosphonates. Facts and Comparisons. 2020. Available from Wolters Kluwer Health, Inc.
6. Humphrey, M, Russell L, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care & Research. 2023;2088-2102.
7. Shoback D, Rosen C, Black D et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update, The Journal of Clinical Endocrinology & Metabolism, Volume 105, Issue 3, March 2020, dga048, <https://doi.org/10.1210/clinem/dga048>.
8. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020;26:1-46.
9. Prolia [prescribing information]. Thousand Oaks, CA: Amgen; March 2024.

Policy History												
#	Date	Change Description										
1.9	Effective Date: 05/27/2025  P&T Date: 04/10/2025	Updated to define osteoporosis, add step for patients who are high-risk thru a bisphosphonate and Prolia, add a step for patients who are very high risk thru zoledronate or denosumab product if zoledronate is contraindicated and defined very high risk, and removed specific timeline for trial of bisphosphonates										
1.8	Effective Date: 04/11/2024	Annual review - no changes made to existing criteria										
1.7	Effective Date: 04/06/2023	Annual review – No changes made to existing criteria										
1.6	Effective Date: 04/14/2022	Updated to allow for clinical situations where patients are not required to use bisphosphonates as first line treatment										
1.5	Effective Date: 10/07/2021	Annual review of criteria was performed, no changes were made.										
1.4	Effective Date: 10/08/2020	Annual review of criteria was performed, no changes were made.										
1.3	Effective Date: 11/07/2019	Policy update: trial and failure of oral and IV bisphosphonate, not to be used with other anabolic agents or denosumab										
1.2	11/01/2019	UM medical management system update for MAPPO and BCNA <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

1.1	Effective Date: 08/01/2019	UM medical management system update for BCBSM <table border="1" data-bbox="483 201 1360 411"> <thead> <tr> <th data-bbox="483 201 959 268">Line of Business</th> <th data-bbox="959 201 1360 268">PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td data-bbox="483 268 959 302">BCBS</td> <td data-bbox="959 268 1360 302">Yes</td> </tr> <tr> <td data-bbox="483 302 959 336">BCN</td> <td data-bbox="959 302 1360 336">Yes</td> </tr> <tr> <td data-bbox="483 336 959 369">MAPPO</td> <td data-bbox="959 336 1360 369">No</td> </tr> <tr> <td data-bbox="483 369 959 403">BCNA</td> <td data-bbox="959 369 1360 403">No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	No											
BCNA	No											
1.0	Effective Date: 06/01/2019	UM medical management system update for BCN New full drug review <table border="1" data-bbox="483 531 1360 741"> <thead> <tr> <th data-bbox="483 531 959 598">Line of Business</th> <th data-bbox="959 531 1360 598">PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td data-bbox="483 598 959 632">BCBS</td> <td data-bbox="959 598 1360 632">No</td> </tr> <tr> <td data-bbox="483 632 959 665">BCN</td> <td data-bbox="959 632 1360 665">Yes</td> </tr> <tr> <td data-bbox="483 665 959 699">MAPPO</td> <td data-bbox="959 665 1360 699">No</td> </tr> <tr> <td data-bbox="483 699 959 732">BCNA</td> <td data-bbox="959 699 1360 732">No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	Yes											
MAPPO	No											
BCNA	No											

\* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.